statistically meaningful improvements in symptoms in short-term studies, overall responses tend to be modest.24–26 This finding has resulted in the recommendation of sufficient drugevaluation trials (i.e., 3 months) as well as possibly higher doses of antidepressants and the use of augmentation strategies.